“…With VMAT techniques, it is possible to conform the doses more closely to the target volumes, thus, minimizing the surrounding volume treated to a high dose level, especially in the head and neck region [21,22,23,24,25,26,27,28]. While the feasibility of accelerated VMAT for LASCCHN patients was investigated [9], few published data are currently available concerning the role of VMAT-SIB plus cetuximab [21,23,24,25,26,27,28].…”